PubMed:7491389 JSON TXT

Annnotations TAB JSON ListView MergeView

Id	Subject	Object	Predicate	Lexical cue
T1	0-34	protein	denotes	Lymphocyte glucocorticoid receptor
T2	468-518	protein	denotes	limbic-hippocampal glucocorticoid type II receptor
T3	520-524	protein	denotes	GCII
T4	548-563	protein	denotes	lymphocyte GCII
T5	739-760	protein	denotes	lymphocyte GCII sites
T6	896-900	protein	denotes	GCII
T7	1007-1011	protein	denotes	GCII
T8	1130-1134	protein	denotes	GCII

Id	Subject	Object	Predicate	Lexical cue
T1	0-10	protein_family_or_group	denotes	Lymphocyte
T2	11-25	lipid	denotes	glucocorticoid
T3	49-59	other_organic_compound	denotes	sertraline
T4	72-108	other_name	denotes	adolescent major depressive disorder
T5	110-113	other_name	denotes	MDD
T6	116-141	other_name	denotes	Major depressive disorder
T7	143-146	other_name	denotes	MDD
T8	151-162	multi_cell	denotes	adolescents
T9	190-215	other_organic_compound	denotes	tricyclic antidepressants
T10	231-248	other_name	denotes	hypercortisolemia
T11	266-295	other_organic_compound	denotes	serotonin reuptake inhibitors
T12	297-301	other_organic_compound	denotes	SRIs
T13	410-445	body_part	denotes	hypothalamic-pituitary-adrenal axis
T14	468-486	protein_molecule	denotes	limbic-hippocampal
T15	487-501	lipid	denotes	glucocorticoid
T16	520-524	protein_molecule	denotes	GCII
T17	548-558	protein_molecule	denotes	lymphocyte
T18	559-563	protein_molecule	denotes	GCII
T19	589-592	other_name	denotes	MDD
T20	637-641	other_organic_compound	denotes	SRIs
T21	667-678	multi_cell	denotes	adolescents
T22	696-714	other_name	denotes	DSM-III-R criteria
T23	719-722	other_name	denotes	MDD
T24	739-749	protein_family_or_group	denotes	lymphocyte
T25	750-754	protein_molecule	denotes	GCII
T26	896-900	protein_molecule	denotes	GCII
T27	933-936	other_organic_compound	denotes	SRI
T28	1007-1011	protein_molecule	denotes	GCII
T29	1048-1058	other_organic_compound	denotes	sertraline
T30	1108-1111	other_organic_compound	denotes	SRI
T31	1130-1134	protein_molecule	denotes	GCII

Id	Subject	Object	Predicate	Lexical cue
C1	0-34	NP	denotes	Lymphocyte glucocorticoid receptor
C2	72-114	NP	denotes	adolescent major depressive disorder (MDD)
C3	116-162	NP	denotes	Major depressive disorder (MDD) in adolescents
C4	266-302	NP	denotes	serotonin reuptake inhibitors (SRIs)
C5	548-563	NP	denotes	lymphocyte GCII
C6	578-592	NP	denotes	adolescent MDD
C7	637-641	NP	denotes	SRIs
C8	896-900	NP	denotes	GCII
C9	933-947	NP	denotes	SRI responders
C10	1007-1011	NP	denotes	GCII
C11	1108-1122	NP	denotes	SRI responders
R1	C3	C2	coref-ident	Major depressive disorder (MDD) in adolescents,adolescent major depressive disorder (MDD)
R2	C5	C1	coref-ident	lymphocyte GCII,Lymphocyte glucocorticoid receptor
R3	C6	C3	coref-ident	adolescent MDD,Major depressive disorder (MDD) in adolescents
R4	C7	C4	coref-ident	SRIs,serotonin reuptake inhibitors (SRIs)
R5	C8	C5	coref-ident	GCII,lymphocyte GCII
R6	C10	C8	coref-ident	GCII,GCII
R7	C11	C9	coref-ident	SRI responders,SRI responders

Id	Subject	Object	Predicate	Lexical cue
S1	0-115	Sentence	denotes	Lymphocyte glucocorticoid receptor: predictor of sertraline response in adolescent major depressive disorder (MDD).
S2	116-249	Sentence	denotes	Major depressive disorder (MDD) in adolescents demonstrates resistance to tricyclic antidepressants and absence of hypercortisolemia.
S3	250-357	Sentence	denotes	The efficacy of serotonin reuptake inhibitors (SRIs) is uncertain, and response predictors are unavailable.
S4	358-526	Sentence	denotes	Abnormal fast feedback and negative feedback of the hypothalamic-pituitary-adrenal axis implicates a dampened limbic-hippocampal glucocorticoid type II receptor (GCII).
S5	527-642	Sentence	denotes	We hypothesized that lymphocyte GCII is altered in adolescent MDD and could serve as a marker for response to SRIs.
S6	643-895	Sentence	denotes	In an open-label study, adolescents (n = 20) meeting DSM-III-R criteria for MDD showed baseline lymphocyte GCII sites per cell (sites/cell) values of 793 +/- 106 versus 2,563 +/- 499 (+/- SEM) for matched controls (n = 18) (t = 3.5; df = 36; p < .001).
S7	896-1006	Sentence	denotes	GCII was bimodally distributed, with SRI responders differing from nonresponders (t = 3.9; df = 14; p < .001).
S8	1007-1102	Sentence	denotes	GCII accurately classified 90 percent of sertraline responders and 80 percent of nonresponders.
S9	1103-1213	Sentence	denotes	Only SRI responders showed GCII sites/cell upregulated after 6 weeks of treatment (t = 2.1, df = 10; p < .05).